Marker Therapeutics (NASDAQ:MRKR) Trading Up 3% – Still a Buy?

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) rose 3% on Monday . The stock traded as high as $1.39 and last traded at $1.37. 43,227 shares were traded during mid-day trading, a decline of 25% from the average session volume of 57,638 shares. The stock had previously closed at $1.33.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Marker Therapeutics Trading Up 3.0%

The firm has a market capitalization of $22.84 million, a PE ratio of -2.25 and a beta of 1.44. The business’s 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.51.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. Analysts forecast that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC purchased a new position in Marker Therapeutics during the fourth quarter worth $222,000. XTX Topco Ltd boosted its stake in shares of Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares during the period. Osaic Holdings Inc. grew its holdings in Marker Therapeutics by 16.5% during the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after purchasing an additional 13,340 shares during the last quarter. Renaissance Technologies LLC raised its position in Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares during the period. Finally, LPL Financial LLC lifted its stake in Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares during the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.